

## Special Issue

# mRNA Vaccines and Monoclonal Antibodies for Therapy

### Message from the Guest Editors

mRNA vaccines and monoclonal antibodies are emerging, promising treatments. mRNA vaccines contain messenger RNA (mRNA) which carries instructions to produce a specific protein. Once inside our body's cells, the mRNA acts as a blueprint to create a viral protein. Then, this protein induces specific antibodies. These antibodies persist for between 4 and 6 months, but immune cells remember how to defend against future infections. mRNA vaccines and monoclonal antibodies show promise in personalized medicine, thereby offering hope for improved outcomes and reduced side effects compared to those of traditional treatments. This Special Issue aims to provide insights into the safe, effective use of mRNA vaccines and of monoclonal antibodies. Novel articles, reviews, and preclinical studies that use human-relevant models or studies on humans are encouraged.

---

### Guest Editors

Dr. Giovanni Genovese

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina 98124, Italy

Dr. Cristina Genovese

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98124 Messina, Italy

---

### Deadline for manuscript submissions

closed (28 February 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/204479](https://mdpi.com/si/204479)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers  
Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).